into essential laboratory tools. Mitchell-Wang is pursuing his Ph.D. at MIT, where he developed a technology that transforms standard microscopes into nanoimaging platforms by magnifying biological samples 20-fold. The method has since been adopted...
options for accessing Eliquis — a medicine relied upon by millions of Americans daily — to the popular Cost Plus Drugs platform,” said Adam Lenkowsky, chief commercial officer, Bristol Myers Squibb. “This new collaboration is grounded in a shared...
quality of life and commonly develop with traditional CAH treatment regimens. The two-year findings provide important information on the durable benefit of treatment with CRENESSITY. Providers can confidently incorporate this additional knowledge...
(FTC). Co-administration with these drugs may decrease the effectiveness of IDVYNSO. See additional selected safety information on the following pages. IDVYNSO (pronounced ihd-VIHN-soh) will be available in pharmacies after May 11. “Advances in HIV...
respectively. About Orthogon Therapeutics: Orthogon is a polyomavirus-focused biotech built on a proprietary discovery platform that fuses structure-based drug design with deep biophysical interrogation of viral proteins, unlocking targets long...
research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, please visit www.avantorsciences.com
include an increased weight capacity of up to 650 pounds5 to accommodate a broader range of patient sizes, a high performance lithium‑ion battery6 that delivers a longer lifespan compared to traditional lead acid batteries and a lower minimum table...
patients can now access Foundayo™ (orforglipron) – Eli Lilly Company's newest oral GLP-1 innovation – on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s. Foundayo™ is a once daily oral treatment for adults...
develop and manufacture high-quality products while maintaining long-term partnerships across the value chain. For more information please visit, www.dexcel-pharma-usa.com
continuous, noninvasive visibility into patients' blood pressure. The module delivers real-time, beat-to-beat arterial waveform data from a noninvasive finger cuff directly to compatible multiparameter patient monitors, helping clinicians close...
Dr. Singal will lead clinical strategy and development as the company advances its initial pipeline focused on transforming care for patients with chronic liver diseases. “Amit is one of the world’s leading authorities on chronic liver disease...
commented, "Entering the K-Pharmacy channel is not just about distribution—it reflects a level of trust earned through formulation expertise and product performance. We will continue to strengthen our presence in professional channels to further...
with neurological conditions, announced its official launch. The company is advancing a proprietary neural interface platform designed to translate brain signals into actionable digital commands, enabling rehabilitation and assistive therapies for...
investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput selection system for...
for Open Innovation Bridging Human, Environment and Materials. The aim objective of ICCBS 2026 is to provide a platform for researchers, engineers, academicians as well as industrial professionals from all over the world to present their research...
to support consistent, patient-friendly dressing changes. By providing the necessary materials in a single, easy-to-use format, carePAC™ aims to reduce complexity for patients and caregivers while supporting adherence to provider-directed wound...
Fisher Scientific the world leader in serving science, announced a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial...
Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline of its Biologics License...
following bispecifics or other BCMA-directed therapies have very limited options. We believe InoPd may deliver a transformative all-oral treatment for RRMM patients and look forward to further evaluating its potential in this Phase 2 trial.” Care...
medicines. He has a strong track record in leading global organizations, scaling operations and driving strategic transformation in complex healthcare environments. Most recently, he served as Group CEO of Pharmanovia, where he led a major...
